Cyclic heptapeptide raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2026-02-09. Anything still debated is marked as such rather than presented as settled.
Receptor activation in hypothalamic and limbic circuits is the mechanism most often cited for the observed effects on sexual desire. Signalling through MC4R couples to Gs proteins and raises intracellular cyclic AMP, which in turn modulates dopaminergic tone in reward-related pathways. Because the peptide reaches the central nervous system after subcutaneous administration, peripheral vascular changes are regarded as secondary rather than primary. The precise neural circuits that translate receptor occupancy into behavioural change remain incompletely mapped, and published accounts describe the pathway in general terms rather than as a fully resolved sequence.
Development began with intranasal formulations investigated for erectile dysfunction, but blood pressure elevation limited that route and prompted a switch to subcutaneous delivery. Clinical testing then shifted toward hypoactive sexual desire disorder in premenopausal women, and a subcutaneous product received United States approval in 2019. Later trials examined other populations with mixed results, and questions about effect size, durability and patient selection remain open in the peer-reviewed literature. Research interest continues in parallel with the broader melanocortin field, where several synthetic analogues are studied together.
Bremelanotide acts as a non-selective agonist at melanocortin receptors, with reported activity at MC1R, MC3R, MC4R and MC5R. The proposed basis for its central effects is activation of MC4R populations in the hypothalamus, a region associated with appetite and reproductive signalling. Because the peptide carries a net positive charge and polar side chains, it does not cross biological membranes freely, which is one reason oral administration is not the standard route. Effects generally appear within an hour of parenteral administration and are described as centrally mediated rather than peripheral.
Bremelanotide, developed under the code PT-141, is a synthetic cyclic heptapeptide analogue of alpha-melanocyte-stimulating hormone. Its structure is Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-OH, with a lactam bridge joining the aspartate and lysine side chains. The molecule has the formula C50H68N14O10 and a monoisotopic mass near 1025 daltons. It is commonly prepared as the acetate salt and appears as a white to off-white lyophilised powder in solid form. The free acid is the pharmacologically relevant species, while the counter-ion improves handling and dissolution.
Early research on PT-141 grew out of work on melanotan II, a related cyclic peptide studied for pigmentation. Investigators observed that centrally acting melanocortin agonists also influenced sexual behaviour in animal models, and the programme shifted toward that endpoint. A nasal formulation was evaluated in clinical trials but showed inconsistent absorption, and later studies used subcutaneous administration instead. Regulatory approval in the United States followed in 2019 for a defined population of premenopausal women with acquired, generalised hypoactive sexual desire disorder. That approval was specific to that group rather than a broad indication.
| Property | Value | Notes |
|---|---|---|
| Research code | PT-141 | Used in early literature before the generic name became common |
| Generic name | Bremelanotide | International nonproprietary name |
| Peptide class | Cyclic heptapeptide | Seven residues joined by a lactam bridge |
| Primary receptor | MC4R | Lower affinity reported at MC1R, MC3R and MC5R |
| Route studied clinically | Subcutaneous injection | Intranasal route was abandoned after pressor effects |
After subcutaneous administration, plasma concentrations rise within roughly thirty minutes and the elimination half-life is short, on the order of two to three hours. Reported physiological responses include transient increases in blood pressure and nausea, which tended to diminish with repeated dosing in trial settings. Because the peptide clears quickly, effects are not expected to persist long after a dose. Absorption from non-injected routes is poorly characterised, and nasal delivery produced variable plasma levels in older work.
Clinical research typically uses randomised, double-blind, placebo-controlled designs. The most common primary endpoint is the desire domain score of the Female Sexual Function Index, sometimes paired with a distress measure. Secondary outcomes include arousal, satisfaction, and event-based counts of satisfying sexual episodes. Across trials, average improvements are modest and individual responses vary widely. Whether benefits persist beyond a few months, and whether they depend on baseline hormone status, remain open questions rather than settled findings.
PT-141 is a synthetic cyclic heptapeptide whose development code is bremelanotide. It belongs to the class of melanocortin receptor agonists and acts by mimicking endogenous peptide hormones. The compound originated from research on melanotan II, where investigators exploring derivatives found distinct pharmacological features. Unlike the parent compound, PT-141 showed effects on pathways related to sexual desire and function in early studies, prompting its development as a separate candidate. Its molecular design aimed to separate receptor activity from pigmentary effects.
The molecular backbone consists of seven amino acid residues joined into a ring through a disulfide bridge. This cyclic conformation is critical for receptor binding. The sequence includes an acetylated N-terminus and an amidated C-terminus, modifications that improve resistance to enzymatic breakdown. One residue is in the D-configuration, a feature that further stabilizes the peptide against protease activity. Together, the ring structure and specific stereochemistry determine selectivity among melanocortin receptor subtypes.
Remains may be exhumed and reburied en masse when a cemetery is relocated, once local planning and religious requirements are met. It also enables construction agencies to clear the way for new constructions. One example of this is cemeteries in Chicago next to O'Hare International Airport to expand the runways. The remains of the Venerable or the Blessed are sometimes exhumed to ensure their bodies lie in their correctly marked graves, as their gravesites usually become places for devotees to gather, and also to collect relics. The bodies may also be transferred to a more dignified place. It also serves the purpose to see if they are supernaturally Incorrupt. An incorrupt corpse is no longer considered miraculous, but it is a characteristic of several known saints. Exhumation is no longer a requirement in the beatification process, but still may be carried out. For ethical and cultural reasons, repatriation and reburial of human remains may be carried out when museums and academic institutions return remains to their place of origin.
Intensive insulin therapy or flexible insulin therapy is a therapeutic regimen for diabetes mellitus treatment. This newer approach contrasts with conventional insulin therapy. Rather than minimize the number of insulin injections per day (a technique which demands a rigid schedule for food and activities), the intensive approach favors flexible meal times with variable carbohydrate as well as flexible physical activities. The trade-off is the increase from 2 or 3 injections per day to 4 or more injections per day, which was considered "intensive" relative to the older approach. In North America in 2004, many endocrinologists prefer the term "flexible insulin therapy" (FIT) to "intensive therapy" and use it to refer to any method of replacing insulin that attempts to mimic the pattern of small continuous basal insulin secretion of a working pancreas combined with larger insulin secretions at mealtimes. The semantic distinction reflects changing treatment.
== E == efficacy – empirical – encephalitis – end-stage disease – endemic – endogenous – endoscopy – endotoxin – endpoint – enteric – enteritis – entry inhibitors – Env – envelope – enzyme – enzyme-linked immunosorbent assay (ELISA) – eosinophil – eosinophilic folliculitis – epidemic – epidemiological surveillance – epidemiology – epithelium – epitope – Epstein-Barr virus (EBV) – erythema – erythema multiforme – erythrocytes – etiology – exogenous – exotoxin – expanded access – experimental drug – expression system
. Even for a simple homogeneous sphere of radius a whose refractive index, n, is very nearly the same as the refractive index "n0" of the suspending fluid, i.e. Rayleigh–Gans approximation, the scattering function in the scattering plane is the relatively complex quantity
=== Europe === Lancaster AMS-UK for trace actinides and radiocarbon at Lancaster University, England Vilnius Radiocarbon AMS dating laboratory in Vilnius, Lithuania Centre for Isotope Research on Cultural and Environmental heritage (CIRCE) [1], Mathematics and Physics Department [2], Università degli Studi della Campania "Luigi Vanvitelli", Caserta, Italy CEREGE in Aix en Provence, France LMC14 Laboratoire de mesure du carbone 14, at LSCE, Saclay, France LSCE-ECHoMICADAS, at LSCE, Gif-sur-Yvette, France 14Chrono Centre for Climate, the Environment, and Chronology Queen's University Belfast, Northern Ireland Bristol Radiocarbon Accelerator Mass Spectrometer at University of Bristol, England RICH, Royal Institute for Cultural heritage, Brussels, Belgium CologneAMS at University of Cologne, Germany Hertelendi Laboratory of Environmental Studies at ATOMKI, Debrecen, Hungary DREAMS at Dresden, Germany Centre for Isotope Research Rijksuniversiteit Groningen, The Netherlands Beta Analytic Europe in London, England Tandem Laboratory at Uppsala University in Uppsala, Sweden Lund Accelerator Mass Spectrometry Facility at Lund University, Sweden RoAMS Laboratory of the "Horia Hulubei" National Institute for Physics and Nuclear Engineering Măgurele, Romania AMS at the Maier-Leibnitz-Laboratory joint facility of LMU Munich and Technical University of Munich, Germany Oxford Radiocarbon Accelerator Unit, University of Oxford, United Kingdom Poznan Radiocarbon Laboratory, Poland Centre for Dating and Diagnostics (CEDAD), University of Salento, Italy [3] Centro Nacional de Aceleradores, CNA University of Sevilla, Spain NERC Recognised Accelerator Mass Spectrometer at SUERC, Scotland Vienna Environmental Research Accelerator at the University of Vienna, Austria Ion Beam Physics Laboratory of the ETH Zurich and the Paul Scherrer Institute, Switzerland National 1MV AMS Laboratory, TÜBİTAK Marmara Research Center Turkey Nuclear Physics Institute, The Czech Academy of Sciences, Czech Republic
Sources: en.wikipedia.org
=== Economics === In 2003, Abbott (AbbVie, Inc.) raised the price of a Norvir course from US$1.71 per day to US$8.57 per day, leading to claims of price gouging by patients' groups and some members of Congress. Consumer group Essential Inventions petitioned the NIH to override the Norvir patent, but the NIH announced on August 4, 2004, that it lacked the legal right to allow generic production of Norvir.
== Interactions == Enobosarm is a substrate of the cytochrome P450 enzyme CYP3A4 and the UDP-glucuronosyltransferase (UGT) enzymes UGT1A1 and UGT2B7. It shows very minimal metabolism by cytochrome P50 enzymes, with CYP3A4 merely responsible for the greatest degree of metabolism. Since enobosarm is metabolized by CYP3A4, UGT1A1, and UGT2B7, inhibitors and inducers of these enzymes can modify the metabolism and pharmacokinetics of enobosarm. The strong CYP3A4 inhibitor itraconazole was shown to have minimal to no influence on the pharmacokinetics of enobosarm, whereas the strong CYP3A4 inducer rifampin reduced enobosarm peak levels by 23%, elimination half-life by 23%, and area-under-the-curve levels by 43%. The pan-UGT inhibitor probenecid was shown to not affect peak levels of enobosarm but to increase the elimination half-life of enobosarm by 78% and to increase area-under-the-curve levels of enobosarm by 50%. Enobosarm had no effect on the pharmacokinetics of celecoxib (a CYP2C9 substrate) or rosuvastatin (a BCRP substrate). Based on the preceding findings, it was concluded that enobosarm poses low risk for clinically relevant drug interactions.
=== Realization === The centrifugal partition chromatograph instrument is constituted with a unique rotor which contains the column. This rotor rotates on its central axis (while HSCCC column rotates on its planetary axis and simultaneously rotates eccentrically about another solar axis). With less vibrations and noise, the CPC offers a typical rotation speed range from 500 to 2000 rpm. Contrary to hydrodynamic CCC, the rotation speed is not directly proportional to the retention volume ratio of the stationary phase. Like DCCC, CPC can be operated in either descending or ascending mode, where the direction is relative to the force generated by the rotor rather than gravity. A redesigned CPC column with larger chambers and channels has been named centrifugal partition extraction (CPE). In the CPE design, faster flow rates and increased column loading can be achieved.
==== Corruption ==== There are also cases of corruption amongst customs officers who work for criminal gangs. The amount of corruption amongst customs officers has more than doubled between 2015 and 2017. In October 2017, Tim Deelen, who worked as a customs officer at the Port of Antwerp, was arrested by the Belgian police. He worked for a criminal organisation based in Antwerp. In September 2017, the federal police in Antwerp was sounding the alarm on the increase of cocaine trafficking in the port city, generating a parallel economy and a level of corruption that was never seen before. Customs officers and police officers very often received a large sum of money (up to €100,000 "to relocate containers to avoid police and customs control") by criminal organisations in Antwerp and the Netherlands, to send drugs through the customs controls without being intercepted. The Dutch Ministry of Justice denied that 95% of all the cocaine that arrived at the Port of Antwerp was transported to the Netherlands, and they also denied the relationship of these drugs to the Dutch networks of the Moroccan mafia. However, writer and criminologist Teun Voeten published a book in 2020 called Drugs, where contradictory claims were made in anonymous interviews by Belgian inmates, and by people from certain neighbourhoods in Antwerp. These claims stated that the number of drugs destined for the Netherlands was around 90%. It also stated that criminal organisations based in the Netherlands functioned as distributors for these drugs.
Sources: en.wikipedia.org
The code designates bremelanotide, a cyclic heptapeptide melanocortin receptor agonist. It served as an internal research identifier before the compound entered formal clinical development. The code and the generic name refer to the same molecule.
MC4R is generally described as the principal target, based on binding affinity and functional assays. Activity at MC1R, MC3R and MC5R is reported as weaker. Receptor selectivity is one reason the compound was pursued for central rather than vascular effects.
Both are synthetic melanocortin analogues built on a similar cyclic peptide scaffold. Bremelanotide is described in the literature as a metabolite-derived analogue of melanotan II rather than the same substance. The two differ in terminal modifications, which affect half-life and receptor profile.
PT-141 was the development code used for bremelanotide during its preclinical and early clinical programme. The peptide is now generally referred to by its international nonproprietary name.